IL-10 Blocks the Development of Resistance to Re-Infection with

English version České info

Despite effective chemotherapy to treat schistosome infections, re-infection rates are extremely high. Resistance to reinfection can develop, however it typically takes several years following numerous rounds of treatment and re-infection, and often develops in only a small cohort of individuals. Using a well-established and highly permissive mouse model, we investigated whether immunoregulatory mechanisms influence the development of resistance. Following Praziquantel (PZQ) treatment of S. mansoni infected mice we observed a significant and mixed anti-worm response, characterized by Th1, Th2 and Th17 responses. Despite the elevated anti-worm response in PBMC's, liver, spleen and mesenteric lymph nodes, this did not confer any protection from a secondary challenge infection. Because a significant increase in IL-10-producing CD4⁺CD44⁺CD25⁺GITR⁺ lymphocytes was observed, we hypothesised that IL-10 was obstructing the development of resistance. Blockade of IL-10 combined with PZQ treatment afforded a greater than 50% reduction in parasite establishment during reinfection, compared to PZQ treatment alone, indicating that IL-10 obstructs the development of acquired resistance. Markedly enhanced Th1, Th2 and Th17 responses, worm-specific IgG1, IgG2b and IgE and circulating eosinophils characterized the protection. This study demonstrates that blocking IL-10 signalling during PZQ treatment can facilitate the development of protective immunity and provide a highly effective strategy to protect against reinfection with S. mansoni.

Vyšlo v časopise: IL-10 Blocks the Development of Resistance to Re-Infection with. PLoS Pathog 7(8): e32767. doi:10.1371/journal.ppat.1002171
Kategorie: Research Article
prolekare.web.journal.doi_sk: https://doi.org/10.1371/journal.ppat.1002171

Souhrn

Zdroje

1. SteinmannPKeiserJBosRTannerMUtzingerJ 2006 Schistosomiasis and water resources development: systematic review, meta-analysis, and estimates of people at risk. Lancet Infect Dis 6 411 425

2. BethonyJMLoukasA 2008 The schistosomiasis research agenda–what now? PLoS Negl Trop Dis 2 e207

3. ColleyDGSecorWE 2007 A schistosomiasis research agenda. PLoS Negl Trop Dis 1 e32

4. HaganP 2009 Schistosomiasis--a rich vein of research. Parasitology 136 1611 1619

5. CioliDValleCAngelucciFMieleAE 2008 Will new antischistosomal drugs finally emerge? Trends Parasitol 24 379 382

6. Abdul-GhaniRALoutfyNHassanA 2009 Experimentally promising antischistosomal drugs: a review of some drug candidates not reaching the clinical use. Parasitol Res 105 899 906

7. MelmanSDSteinauerMLCunninghamCKubatkoLSMwangiIN 2009 Reduced susceptibility to praziquantel among naturally occurring Kenyan isolates of Schistosoma mansoni. PLoS Negl Trop Dis 3 e504

8. DoenhoffMJCioliDUtzingerJ 2008 Praziquantel: mechanisms of action, resistance and new derivatives for schistosomiasis. Curr Opin Infect Dis 21 659 667

9. HotezPJBethonyJMOliveiraSCBrindleyPJLoukasA 2008 Multivalent anthelminthic vaccine to prevent hookworm and schistosomiasis. Expert Rev Vaccines 7 745 752

10. OliveiraSCFonsecaCTCardosoFCFariasLPLeiteLC 2008 Recent advances in vaccine research against schistosomiasis in Brazil. Acta Trop 108 256 262

11. PearceEJ 2003 Progress towards a vaccine for schistosomiasis. Acta Trop 86 309 313

12. WuZDLuZYYuXB 2005 Development of a vaccine against Schistosoma japonicum in China: a review. Acta Trop 96 106 116

13. SilveiraAMFragaLAPrataACorrea-OliveiraRAddissDA 1998 Resistance to infection/reinfection by Schistosoma mansoni is not augmented by three treatments with 45 days intervals. Mem Inst Oswaldo Cruz 93 113 114

14. GryseelsB 1994 Human resistance to Schistosoma infections: age or experience? Parasitol Today 10 380 384

15. MutapiFNdhlovuPDHaganPSpicerJTMduluzaT 1998 Chemotherapy accelerates the development of acquired immune responses to Schistosoma haematobium infection. J Infect Dis 178 289 293

16. EtardJFAudibertMDaboA 1995 Age-acquired resistance and predisposition to reinfection with Schistosoma haematobium after treatment with praziquantel in Mali. Am J Trop Med Hyg 52 549 558

17. ButterworthAECapronMCordingleyJSDaltonPRDunneDW 1985 Immunity after treatment of human schistosomiasis mansoni. II. Identification of resistant individuals, and analysis of their immune responses. Trans R Soc Trop Med Hyg 79 393 408

18. KaranjaDMHightowerAWColleyDGMwinziPNGalilK 2002 Resistance to reinfection with Schistosoma mansoni in occupationally exposed adults and effect of HIV-1 co-infection on susceptibility to schistosomiasis: a longitudinal study. Lancet 360 592 596

19. BrownMMawaPAJosephSBukusubaJWateraC 2005 Treatment of Schistosoma mansoni infection increases helminth-specific type 2 cytokine responses and HIV-1 loads in coinfected Ugandan adults. J Infect Dis 191 1648 1657

20. JosephSJonesFMWalterKFulfordAJKimaniGMwatha 2004 Increases in human T helper 2 cytokine responses to Schistosoma mansoni worm and worm-tegument antigens are induced by treatment with praziquantel. J Infect Dis 190 835 842

21. BettelliECarrierYGaoWKornTStromTB 2006 Reciprocal developmental pathways for the generation of pathogenic effector TH17 and regulatory T cells. Nature 441 235 238

22. KamanakaMKimSTWanYYSutterwalaFSLara-TejeroM 2006 Expression of interleukin-10 in intestinal lymphocytes detected by an interleukin-10 reporter knockin tiger mouse. Immunity 25 941 952

23. WilsonMSElnekaveEMentink-KaneMMHodgesMGPesceJT 2007 IL-13Ralpha2 and IL-10 coordinately suppress airway inflammation, airway-hyperreactivity, and fibrosis in mice. J Clin Invest 117 2941 2951

24. FinkelmanFDMorrisSC 1999 Development of an assay to measure in vivo cytokine production in the mouse. Int Immunol 11 1811 1818

25. BeckerBMehlhornHAndrewsPThomasHEckertJ 1980 Light and electron microscopic studies on the effect of praziquantel on Schistosoma mansoni, Dicrocoelium dendriticum, and Fasciola hepatica (Trematoda) in vitro. Z Parasitenkd 63 113 128

26. ShuhuaXBingguiSCholletJTannerM 2000 Tegumental changes in adult Schistosoma mansoni harboured in mice treated with praziquantel enantiomers. Acta Trop 76 107 117

27. DoenhoffMJSabahAAFletcherCWebbeGBainJ 1987 Evidence for an immune-dependent action of praziquantel on Schistosoma mansoni in mice. Trans R Soc Trop Med Hyg 81 947 951

28. FallonPGCooperROProbertAJDoenhoffMJ 1992 Immune-dependent chemotherapy of schistosomiasis. Parasitology 105 Suppl S41 48

29. CoutinhoHMAcostaLPMcGarveySTJarillaBJizM 2006 Nutritional status improves after treatment of schistosoma japonicum-infected children and adolescents. J Nutr 136 183 188

30. ColleyDGBarsoumISDahawiHSGamilFHabibM 1986 Immune responses and immunoregulation in relation to human schistosomiasis in Egypt. III. Immunity and longitudinal studies of in vitro responsiveness after treatment. Trans R Soc Trop Med Hyg 80 952 957

31. GroganJLKremsnerPGDeelderAMYazdanbakhshM 1996 Elevated proliferation and interleukin-4 release from CD4+ cells after chemotherapy in human Schistosoma haematobium infection. Eur J Immunol 26 1365 1370

32. La FlammeACMacDonaldASHuxtableCRCarrollMPearceEJ 2003 Lack of C3 affects Th2 response development and the sequelae of chemotherapy in schistosomiasis. J Immunol 170 470 476

33. GoldDLengyJ 1975 Failure to immunise mice against Schistosoma mansoni by therapeutic eradication of the adult worm burden. Ann Trop Med Parasitol 69 265 266

34. SturrockRFBensted-SmithRButterworthAEDaltonPRKariukiHC 1987 Immunity after treatment of human schistosomiasis mansoni. III. Long-term effects of treatment and retreatment. Trans R Soc Trop Med Hyg 81 303 314

35. FulfordAJWebsterMOumaJHKimaniGDunneDW 1998 Puberty and Age-related Changes in Susceptibility to Schistosome Infection. Parasitol Today 14 23 26

36. KurtisJDFriedmanJFLeenstraTLangdonGCWuHW 2006 Pubertal development predicts resistance to infection and reinfection with Schistosoma japonicum. Clin Infect Dis 42 1692 1698

37. BlackCLMwinziPNMuokEMAbudhoBFitzsimmonsCM 2010 Influence of exposure history on the immunology and development of resistance to human Schistosomiasis mansoni. PLoS Negl Trop Dis 4 e637

38. KimaniGChungeCNButterworthAEKamauTBwayoJ 1991 Eosinophilia and eosinophil helminthotoxicity in patients treated for Schistosoma mansoni infections. Trans R Soc Trop Med Hyg 85 489 492

39. MitchellGFDavernKMWoodSMWrightMDArgyropoulosVP 1990 Attempts to induce resistance in mice to Schistosoma japonicum and Schistosoma mansoni by exposure to crude schistosome antigens plus cloned glutathione-S-transferases. Immunol Cell Biol 68 Pt 6 377 385

40. WoolhouseMEHaganP 1999 Seeking the ghost of worms past. Nat Med 5 1225 1227

41. McHughSMCoulsonPSWilsonRA 1987 The relationship between pathology and resistance to reinfection with Schistosoma mansoni in mice: a causal mechanism of resistance in chronic infections. Parasitology 94 Pt 1 81 91

42. van den BiggelaarAHBorrmannSKremsnerPYazdanbakhshM 2002 Immune responses induced by repeated treatment do not result in protective immunity to Schistosoma haematobium: interleukin (IL)-5 and IL-10 responses. J Infect Dis 186 1474 1482

43. LeenstraTAcostaLPWuHWLangdonGC SolomonJS 2006 T-helper-2 cytokine responses to Sj97 predict resistance to reinfection with Schistosoma japonicum. Infect Immun 74 370 381

44. CaldasIRCampi-AzevedoACOliveiraLFSilveiraAMOliveiraRC 2008 Human schistosomiasis mansoni: immune responses during acute and chronic phases of the infection. Acta Trop 108 109 117

45. MutapiFWinbornGMidziNTaylorMMduluzaT 2007 Cytokine responses to Schistosoma haematobium in a Zimbabwean population: contrasting profiles for IFN-gamma, IL-4, IL-5 and IL-10 with age. BMC Infect Dis 7 139

46. SherAFiorentinoDCasparPPearceEMosmannT 1991 Production of IL-10 by CD4+ T lymphocytes correlates with down-regulation of Th1 cytokine synthesis in helminth infection. J Immunol 147 2713 2716

47. Flores VillanuevaPOChikunguwoSMHarrisTSStadeckerMJ 1993 Role of IL-10 on antigen-presenting cell function for schistosomal egg-specific monoclonal T helper cell responses in vitro and in vivo. J Immunol 151 3192 3198

48. Flores-VillanuevaPOZhengXXStromTBStadeckerMJ 1996 Recombinant IL-10 and IL-10/Fc treatment down-regulate egg antigen-specific delayed hypersensitivity reactions and egg granuloma formation in schistosomiasis. J Immunol 156 3315 3320

49. BosshardtSCFreemanGLJrSecorWEColleyDG 1997 IL-10 deficit correlates with chronic, hypersplenomegaly syndrome in male CBA/J mice infected with Schistosoma mansoni. Parasite Immunol 19 347 353

50. WynnTAMorawetzRScharton-KerstenTHienySMorseHC 1997 Analysis of granuloma formation in double cytokine-deficient mice reveals a central role for IL-10 in polarizing both T helper cell 1- and T helper cell 2-type cytokine responses in vivo. J Immunol 159 5014 5023

51. WynnTACheeverAWWilliamsMEHienySCasparPKuhnRMullerW 1998 IL-10 regulates liver pathology in acute murine Schistosomiasis mansoni but is not required for immune down-modulation of chronic disease. J Immunol 160 4473 4480

52. HoffmannKFCheeverAWWynnTA 2000 IL-10 and the dangers of immune polarization: excessive type 1 and type 2 cytokine responses induce distinct forms of lethal immunopathology in murine schistosomiasis. J Immunol 164 6406 6416

53. HesseMPiccirilloCABelkaidYPruferJMentink-KaneM 2004 The pathogenesis of schistosomiasis is controlled by cooperating IL-10-producing innate effector and regulatory T cells. J Immunol 172 3157 3166

54. ManganNEFallonRESmithPvan RooijenNMcKenzieAN 2004 Helminth infection protects mice from anaphylaxis via IL-10-producing B cells. J Immunol 173 6346 6356

55. FreemanCMChiuBCStolbergVRHuJZeibecoglouK 2005 CCR8 is expressed by antigen-elicited, IL-10-producing CD4+CD25+ T cells, which regulate Th2-mediated granuloma formation in mice. J Immunol 174 1962 1970

56. SadlerCHRutitzkyLIStadeckerMJWilsonRA 2003 IL-10 is crucial for the transition from acute to chronic disease state during infection of mice with Schistosoma mansoni. Eur J Immunol 33 880 888

57. HerbertDROrekovTPerkinsCFinkelmanFD 2008 IL-10 and TGF-beta redundantly protect against severe liver injury and mortality during acute schistosomiasis. J Immunol 181 7214 7220

58. MontenegroSMMirandaPMahantySAbathFGTeixeiraKM 1999 Cytokine production in acute versus chronic human Schistosomiasis mansoni: the cross-regulatory role of interferon-gamma and interleukin-10 in the responses of peripheral blood mononuclear cells and splenocytes to parasite antigens. J Infect Dis 179 1502 1514

59. FalcaoPLMalaquiasLCMartins-FilhoOASilveiraAMPassosVM 1998 Human Schistosomiasis mansoni: IL-10 modulates the in vitro granuloma formation. Parasite Immunol 20 447 454

60. Correa-OliveiraRMalaquiasLCFalcaoPLVianaIRBahia-OliveiraLM 1998 Cytokines as determinants of resistance and pathology in human Schistosoma mansoni infection. Braz J Med Biol Res 31 171 177

61. MalaquiasLCFalcaoPLSilveiraAMGazzinelliGPrataA 1997 Cytokine regulation of human immune response to Schistosoma mansoni: analysis of the role of IL-4, IL-5 and IL-10 on peripheral blood mononuclear cell responses. Scand J Immunol 46 393 398

62. HoffmannKFJamesSLCheeverAWWynnTA 1999 Studies with double cytokine-deficient mice reveal that highly polarized Th1- and Th2-type cytokine and antibody responses contribute equally to vaccine-induced immunity to Schistosoma mansoni. J Immunol 163 927 938

63. HoggKGKumkateSMountfordAP 2003 IL-10 regulates early IL-12-mediated immune responses induced by the radiation-attenuated schistosome vaccine. Int Immunol 15 1451 1459

64. AndersonCFLiraRKamhawiSBelkaidYWynnTASacksD 2008 IL-10 and TGF-beta control the establishment of persistent and transmissible infections produced by Leishmania tropica in C57BL/6 mice. J Immunol 180 4090 4097

65. BelkaidYHoffmannKFMendezSKamhawiSUdeyMC 2001 The role of interleukin (IL)-10 in the persistence of Leishmania major in the skin after healing and the therapeutic potential of anti-IL-10 receptor antibody for sterile cure. J Exp Med 194 1497 1506

66. BelkaidYPiccirilloCAMendezSShevachEMSacksDL 2002 CD4+CD25+ regulatory T cells control Leishmania major persistence and immunity. Nature 420 502 507

67. CouperKNBlountDGWilsonMSHafallaJCBelkaidY 2008 IL-10 from CD4CD25Foxp3CD127 adaptive regulatory T cells modulates parasite clearance and pathology during malaria infection. PLoS Pathog 4 e1000004

68. BinLHowellMDKimBEHallCFStreibJELeungDY 2009 Inhibition of S100A11 gene expression impairs keratinocyte response against vaccinia virus through downregulation of the IL-10 receptor 2 chain. J Allergy Clin Immunol 124 270 277, 277 e271

69. BrooksDGLeeAMElsaesserHMcGavernDBOldstoneMB 2008 IL-10 blockade facilitates DNA vaccine-induced T cell responses and enhances clearance of persistent virus infection. J Exp Med 205 533 541

70. DarrahPAHegdeSTPatelDTLindsayRWChenL 2010 IL-10 production differentially influences the magnitude, quality, and protective capacity of Th1 responses depending on the vaccine platform. J Exp Med 207 1421 1433

71. IgietsemeJUAnanabaGABolierJBowersSMooreT 2000 Suppression of endogenous IL-10 gene expression in dendritic cells enhances antigen presentation for specific Th1 induction: potential for cellular vaccine development. J Immunol 164 4212 4219

72. RobertsMTStoberCBMcKenzieANBlackwellJM 2005 Interleukin-4 (IL-4) and IL-10 collude in vaccine failure for novel exacerbatory antigens in murine Leishmania major infection. Infect Immun 73 7620 7628

73. SilvaRAPaisTFAppelbergR 2001 Blocking the receptor for IL-10 improves antimycobacterial chemotherapy and vaccination. J Immunol 167 1535 1541

74. LiaoGNayakSRegueiroJRBergerSBDetreC 2010 GITR engagement preferentially enhances proliferation of functionally competent D4+CD25+FoxP3+ regulatory T cells. Int Immunol 22 259 270

75. MottaACVissersJLGrasRVan EschBCVan OosterhoutAJ 2009 GITR signaling potentiates airway hyperresponsiveness by enhancing Th2 cell activity in a mouse model of asthma. Respir Res 10 93

76. WilsonRA 1990 Leaky livers, portal shunting and immunity to schistosomes. Parasitol Today 6 354 358

77. RobertsMButterworthAEKimaniGKamauTFulfordAJ 1993 Immunity after treatment of human schistosomiasis: association between cellular responses and resistance to reinfection. Infect Immun 61 4984 4993

78. ButterworthAEDaltonPRDunneDWMugambiMOumaJH 1984 Immunity after treatment of human schistosomiasis mansoni. I. Study design, pretreatment observations and the results of treatment. Trans R Soc Trop Med Hyg 78 108 123

79. Ganley-LealLMMwinziPNCetre-SossahCBAndoveJHightowerAW 2006 Correlation between eosinophils and protection against reinfection with Schistosoma mansoni and the effect of human immunodeficiency virus type 1 coinfection in humans. Infect Immun 74 2169 2176

80. Ganley-LealLMMwinziPNCetre-SossahCBAndoveJHightowerAW 2006 Higher percentages of circulating mast cell precursors correlate with susceptibility to reinfection with Schistosoma mansoni. Am J Trop Med Hyg 75 1053 1057

81. HaganPBlumenthalUJDunnDSimpsonAJWilkinsHA 1991 Human IgE, IgG4 and resistance to reinfection with Schistosoma haematobium. Nature 349 243 245

82. DunneDWButterworthAEFulfordAJKariukiHCLangleyJG 1992 Immunity after treatment of human schistosomiasis: association between IgE antibodies to adult worm antigens and resistance to reinfection. Eur J Immunol 22 1483 1494

83. CaldasIRCorrea-OliveiraRColosimoECarvalhoOSMassaraCL 2000 Susceptibility and resistance to Schistosoma mansoni reinfection: parallel cellular and isotypic immunologic assessment. Am J Trop Med Hyg 62 57 64

84. DunneDWWebsterMSmithPLangleyJGRichardsonBA 1997 The isolation of a 22 kDa band after SDS-PAGE of Schistosoma mansoni adult worms and its use to demonstrate that IgE responses against the antigen(s) it contains are associated with human resistance to reinfection. Parasite Immunol 19 79 89

85. DemeureCERihetPAbelLOuattaraMBourgoisA 1993 Resistance to Schistosoma mansoni in humans: influence of the IgE/IgG4 balance and IgG2 in immunity to reinfection after chemotherapy. J Infect Dis 168 1000 1008

86. DunneDWButterworthAEFulfordAJOumaJHSturrockRF 1992 Human IgE responses to Schistosoma mansoni and resistance to reinfection. Mem Inst Oswaldo Cruz 87 Suppl 4 99 103

87. MwinziPNGanley-LealLBlackCLSecorWEKaranjaDM 2009 Circulating CD23+ B cell subset correlates with the development of resistance to Schistosoma mansoni reinfection in occupationally exposed adults who have undergone multiple treatments. J Infect Dis 199 272 279